Abbott’s FreeStyle Libre Dominates CGM; CardioMEMS HERO Gains FDA Approval
Abbott’s FreeStyle Libre leads global CGM as FDA approves CardioMEMS HERO and VERITAS study shows promising Amulet 360 closure rates. The personalized nutrition market is forecast to grow from $15.80 billion in 2025 to $60.92 billion by 2035 at a 15.04% CAGR, offering a consumer health growth opportunity.
1. Abbott’s CGM and CardioMEMS Advances
Abbott’s FreeStyle Libre continues to dominate global CGM adoption across Type 1 and Type 2 diabetes, while FDA approval of the CardioMEMS HERO device expands its heart failure portfolio with a next-generation pulmonary artery pressure reader. Early VERITAS study results demonstrated meaningful closure rates for the Amulet 360 left atrial appendage occluder in non-valvular atrial fibrillation patients.
2. Personalized Nutrition Market Outlook
The global personalized nutrition market is projected to increase from $15.80 billion in 2025 to $60.92 billion by 2035 at a 15.04% CAGR, driven by growing preventive healthcare awareness, rising chronic disease rates and demand for DNA-based and AI-powered wellness solutions. The U.S. segment is expected to reach $22.27 billion by 2035 at a 15.11% CAGR.